| Literature DB >> 29249655 |
Lingtao Jin1, Jaemoo Chun2, Chaoyun Pan2, Avi Kumar3, Guojing Zhang2, Youna Ha2, Dan Li2, Gina N Alesi2, Yibin Kang4, Lu Zhou5, Wen-Mei Yu6, Kelly R Magliocca7, Fadlo R Khuri2, Cheng-Kui Qu8, Christian Metallo3, Taofeek K Owonikoko2, Sumin Kang9.
Abstract
Loss of LKB1 is associated with increased metastasis and poor prognosis in lung cancer, but the development of targeted agents is in its infancy. Here we report that a glutaminolytic enzyme, glutamate dehydrogenase 1 (GDH1), upregulated upon detachment via pleomorphic adenoma gene 1 (PLAG1), provides anti-anoikis and pro-metastatic signals in LKB1-deficient lung cancer. Mechanistically, the GDH1 product α-KG activates CamKK2 by enhancing its substrate AMPK binding, which contributes to energy production that confers anoikis resistance. The effect of GDH1 on AMPK is evident in LKB1-deficient lung cancer, where AMPK activation predominantly depends on CamKK2. Targeting GDH1 with R162 attenuated tumor metastasis in patient-derived xenograft model and correlation studies in lung cancer patients further validated the clinical relevance of our finding. Our study provides insight into the molecular mechanism by which GDH1-mediated metabolic reprogramming of glutaminolysis mediates lung cancer metastasis and offers a therapeutic strategy for patients with LKB1-deficient lung cancer.Entities:
Keywords: AMPKa; CamKK2; GLUD1; LKB1 deficient; anoikis; metastasis
Mesh:
Substances:
Year: 2017 PMID: 29249655 PMCID: PMC5777230 DOI: 10.1016/j.molcel.2017.11.025
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970